Correction

Dr. Kannayiram Alagiakrishnan, wishes to apologise for the omission of the competing interests statements, which were not published alongside the article. These statements are now published below:

Peter N. McCracken: In the last three years I have received grant research support from Pfizer, Eisai, Sanofi-aventis, Lundbeck Canada, Servier Canada, Janssen-Ortho, and Neurochem Inc, Syreon Corporation and Wyeth. I have served as a consultant for Pfizer, Eisai, Novartis, Lundbeck Canada, and Janssen Ortho. I have been on the Speaker's Bureau or served in CME programs with Pfizer, Eisai, Novartis, Lundbeck and Janssen Ortho. I am not a shareholder in these firms and receive no other financial or material support.

Howard Feldman: In the last three years, I have/have had a financial interest/arrangement or affiliation with the following organizations: Grant/Research Support (External):Pfizer, Eisai, Janssen, Lilly, Astra Zeneca, Sanofi Synthelabo, Glaxo Smith Kline. Consultant: Pfizer, Eisai, Novartis, Janssen, Servier, Sanofi Synthelabo, Glaxo Smith Kline, Myriad, Targacept, Lundbeck, Forest, Axonyx. Speakers’ Bureau or CME programs:Pfizer, Eisai, Janssen, Novartis, Forest For this specific article the reader should be aware that I have had financial arrangements with Pfizer, Eisai, Novartis and Janssen as listed above. They are the manufacturers of the acetylcholinesterase inhibitors. Pfizer is also the manufacturer of atorvastatin, a statin that is being investigated in AD and for which I have been a consultant.

Kannayiram Alagiakrishnan: In the last three years I have received research support from Janssen-Ortho.